Literature DB >> 17295355

A proteomic investigation of glomerular podocytes from a Denys-Drash syndrome patient with a mutation in the Wilms tumour suppressor gene WT1.

Rebecca L Viney1, Avril A Morrison, Lambert P van den Heuvel, Lan Ni, Peter W Mathieson, Moin A Saleem, Michael R Ladomery.   

Abstract

Glomerular podocytes are essential for blood filtration in the kidney underpinned by their unique cytoskeletal morphology. An increasing number of kidney diseases are being associated with key podocyte abnormalities. The Wilms tumour suppressor gene (WT1) encodes a zinc finger protein with a crucial role in normal kidney development; and in the adult, WT1 is required for normal podocyte function. Denys-Drash Syndrome (DDS) results from mutations affecting the zinc finger domain of WT1. The aim of this study was to undertake, for the first time, a proteomic analysis of cultured human podocytes; and to analyse the molecular changes in DDS podocytes. The morphology of DDS podocytes was highly irregular, reminiscent of a fibroblastic appearance. A reference 2-D gel was generated, and 75 proteins were identified of which 43% involved in cytoskeletal architecture. The DDS and wild-type proteomes were compared by 2-D DIGE. The level of 95.6% of proteins was unaltered; but 4.4% were altered more than two-fold. A sample of proteins involved in cytoskeletal architecture appeared to be misexpressed in DDS podocytes. Consistent with this finding, overall levels of filamentous actin also appeared reduced in DDS podocytes. We conclude that one of WT1 functions in podocytes is to regulate the expression of key components and regulators of the cytoskeleton.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17295355     DOI: 10.1002/pmic.200600666

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  8 in total

Review 1.  Role of the Wilms' tumour transcription factor, Wt1, in blood vessel formation.

Authors:  Holger Scholz; Kay-Dietrich Wagner; Nicole Wagner
Journal:  Pflugers Arch       Date:  2008-12-04       Impact factor: 3.657

Review 2.  The podocyte as a target: cyclosporin A in the management of the nephrotic syndrome caused by WT1 mutations.

Authors:  Constantinos J Stefanidis; Uwe Querfeld
Journal:  Eur J Pediatr       Date:  2011-02-08       Impact factor: 3.183

3.  A novel WT1 gene mutation in a three-generation family with progressive isolated focal segmental glomerulosclerosis.

Authors:  Elisa Benetti; Gianluca Caridi; Cristina Malaventura; Monica Dagnino; Emanuela Leonardi; Lina Artifoni; Gian Marco Ghiggeri; Silvio C E Tosatto; Luisa Murer
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-11       Impact factor: 8.237

4.  Proteomic analysis identifies insulin-like growth factor-binding protein-related protein-1 as a podocyte product.

Authors:  Takayuki Matsumoto; Sonja Hess; Hiroshi Kajiyama; Toru Sakairi; Moin A Saleem; Peter W Mathieson; Yoshihisa Nojima; Jeffrey B Kopp
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-14

5.  Conditionally immortalized human podocyte cell lines established from urine.

Authors:  Toru Sakairi; Yoshifusa Abe; Hiroshi Kajiyama; Linda D Bartlett; Lilian V Howard; Parmijit S Jat; Jeffrey B Kopp
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-02

6.  WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

Authors:  Elianna M Amin; Sebastian Oltean; Jing Hua; Melissa V R Gammons; Maryam Hamdollah-Zadeh; Gavin I Welsh; Man-Kim Cheung; Lan Ni; Satoru Kase; Emma S Rennel; Kirsty E Symonds; Dawid G Nowak; Brigitte Royer-Pokora; Moin A Saleem; Masatoshi Hagiwara; Valérie A Schumacher; Steven J Harper; David R Hinton; David O Bates; Michael R Ladomery
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

7.  Oxygen-Dependent Gene Expression in Development and Cancer: Lessons Learned from the Wilms' Tumor Gene, WT1.

Authors:  Holger Scholz; Karin M Kirschner
Journal:  Front Mol Neurosci       Date:  2011-02-24       Impact factor: 5.639

8.  The LIM and SH3 domain protein family: structural proteins or signal transducers or both?

Authors:  Thomas G P Grunewald; Elke Butt
Journal:  Mol Cancer       Date:  2008-04-17       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.